For the first time in the program’s history, Medicare is covering weight-loss drugs, and the price tag looks almost too good to pass up.
Beginning July 1, eligible Part D enrollees can access medications including Wegovy, Foundayo, and the Zepbound KwikPen for a flat $50 monthly copay through a temporary federal demonstration called the Medicare GLP-1 (glucagon-like peptide-1) Bridge
That is a massive discount compared to the retail price of these drugs, which can exceed $1,000 per month without insurance coverage. It arrives at a moment when roughly 56% of GLP-1 users say affordability is a significant challenge, a poll from KFF, the health policy research organization, found. But this is not traditional Part D coverage, and the distinction creates financial consequences that could blindside enrollees who assume the program works like every other Medicare prescription benefit they have used.
How the GLP-1 Bridge $50 copay falls outside Part D’s safety net The GLP-1 Bridge operates entirely outside the Part D benefit structure, and that separation has three practical effects that enrollees need to understand before filling a prescription. – The $50 monthly copay does not count toward the Part D deductible or the $2,100 annual out-of-pocket spending cap for 2026, which rises to $2,400 in 2027, the Centers for Medicare & Medicaid Services confirmed. – Enrollees who receive the Low-Income Subsidy, also known as Extra Help, cannot apply that cost-sharing assistance to Bridge program copays, a KFF analysis noted. – The copay is not eligible for the Medicare Prescription Payment Plan, which lets beneficiaries spread out-of-pocket drug costs throughout the calendar year. “Not only do the costs not count toward your out-of-pocket cap, your deductible or anything like that, if there is a problem, you also need to go to Medicare. You do not go to your plan,” Leigh Purvis, prescription drug policy principal at AARP’s Public Policy Institute, said. For a beneficiary who stays…